Semax Dosing Guide: Research Protocols for the Russian Nootropic Neuropeptide

Semax is a synthetic heptapeptide developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences by the groups of Ivan P. Ashmarin and Nikolai F. Myasoedov. Its sequence (Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP) attaches a stabilising Pro-Gly-Pro tail to the 4-7 fragment of adrenocorticotropic hormone (ACTH). That single design decision changes everything about how the molecule behaves: ACTH 4-7 itself is cleaved in seconds by brain and plasma peptidases, whereas Semax persists long enough to drive profound transcriptional effects on brain-derived neurotrophic factor and nerve growth factor. In Russia, Semax is a registered medicine for ischaemic stroke and optic nerve disorders. Outside Russia, it is an unlicensed research peptide that biohackers, neuroscience research teams, and sports-medicine groups use as a nootropic reference compound.

This guide covers the pharmacology, dosing ranges, intranasal reconstitution math, and the two comparisons researchers ask about most: Semax versus Selank, and Semax versus N-Acetyl-Semax. The target reader is a research-minded user who already understands mg, mcg, and the distinction between an approved medicine and an investigational compound. Everything that follows is written for that context.

What Is Semax?

Semax is a seven-residue peptide of molecular formula C37H51N9O10S, molecular weight 813.93 g/mol, CAS registry number 80714-61-0. Structurally it is ACTH 4-7 (Met-Glu-His-Phe), the melanocortin core of adrenocorticotropic hormone, extended at the C-terminus with Pro-Gly-Pro. The parent ACTH 4-7 tetrapeptide is biologically interesting but pharmacologically impossible, it survives in plasma only seconds. The Pro-Gly-Pro tail is chemically simple but functionally revolutionary: it blocks the carboxypeptidases that would otherwise destroy the peptide and allows enough residence time for nose-to-brain transport, receptor engagement, and downstream gene-expression effects.

In the Russian pharmacopoeia, Semax is registered in two concentrations. Semax 0.1 percent nasal drops are used for cognitive disorders, asthenia, and prophylaxis in high-stress cognitive tasks. Semax 1 percent nasal drops (sold under the brand name Semax 1 percent or "Semax-Hept") is registered for ischaemic stroke in the acute phase and for optic nerve atrophy. The stroke indication is unusual among peptide neuroprotectants because it survived large enough Russian trials to obtain formal registration.

Outside Russia, Semax is sold exclusively as a research-use chemical, supplied as lyophilised white powder in glass vials at ≥99 percent purity by HPLC with mass spectrometric identity confirmation. It has no Food and Drug Administration or European Medicines Agency approval and is handled as an investigational compound.

Mechanism of Action

The central mechanism of Semax is a rapid and measurable upregulation of BDNF and NGF messenger RNA in the hippocampus, prefrontal cortex, and basal forebrain within hours of a single intranasal dose. This is not a side effect or downstream consequence, it is the core pharmacology. Transcriptomic work by Kolomin, Shadrina, Slominsky, and Limborska at the Institute of Molecular Genetics documented differential expression of hundreds of genes after a single Semax dose in rodents, with the strongest and most reproducible changes in neurotrophin and synaptic plasticity pathways.

Downstream of the neurotrophin surge, Semax modulates classical monoamine systems. Dopamine turnover in the striatum increases, consistent with improved performance on attention and working memory tasks. Serotonergic modulation is more modest, and the compound does not produce the anxiolytic-sedative spectrum characteristic of serotonergic anxiolytics or benzodiazepines. Acetylcholine release in the hippocampus is elevated, which aligns with the cognitive-enhancing behavioural phenotype in rodent mazes.

The melanocortin parent motif is functionally active. Semax partially engages melanocortin MC3 and MC4 receptors, although it is neither a full agonist nor a selective compound at those sites. The melanocortin arm contributes to HPA-axis normalisation under stress load and to the anti-inflammatory tone that accompanies chronic Semax dosing. Separately, like its sister peptide Selank, Semax inhibits enkephalin-degrading enzymes, which prolongs endogenous opioid-peptide tone and contributes to the anti-stress behavioural signature.

Neuroprotection arm

The ischaemic-stroke indication is driven by a distinct set of effects. In rodent middle cerebral artery occlusion models, Semax reduces infarct volume, preserves sensorimotor function, and improves survival. The mechanism combines the BDNF/NGF surge with suppression of apoptotic cascades and with anti-inflammatory cytokine modulation. Russian acute-stroke protocols use intranasal Semax within the first 24 hours of ischaemic event presentation, typically for 5 to 10 days.

Pharmacokinetics and Half-Life

Semax is given intranasally because oral bioavailability is effectively zero, gastric and small-intestinal peptidases destroy the peptide on contact. Intranasal delivery bypasses this and provides partial direct nose-to-brain transport through olfactory and trigeminal pathways, alongside systemic absorption across the respiratory mucosa. Cerebrospinal fluid concentrations rise within approximately 30 minutes of an intranasal dose and are reported to reach roughly 60 to 70 percent of corresponding plasma concentrations in rodent studies, a striking ratio for a peptide of this size.

The parent peptide has a plasma half-life of only 2 to 5 minutes. The behavioural and molecular effects last orders of magnitude longer. Three mechanisms account for the mismatch. First, Semax is metabolised to Pro-Gly-Pro (PGP), which is itself biologically active and accumulates in brain tissue with a substantially longer half-life. Second, the BDNF and NGF mRNA upregulation triggered by a single dose continues for 12 to 24 hours and drives sustained behavioural change. Third, the inhibition of enkephalinases produces a lasting elevation of endogenous opioid-peptide tone.

The practical consequence is that dose frequency is governed by downstream signalling windows, not plasma kinetics. Most published Russian protocols use once- or twice-daily dosing even though the parent peptide disappears from plasma within minutes.

Research Evidence

The Semax literature is dominated by Russian-language clinical and preclinical work, with a smaller but growing Western peer-reviewed presence focused on mechanism. The key stroke registration data come from multi-centre Russian clinical trials in the 1990s and 2000s, showing reduced neurological deficit on standardised rating scales and improved functional recovery when intranasal Semax 1 percent was added to standard acute-stroke care within the first 24 hours of symptom onset.

Cognitive and nootropic evidence is broader. Russian studies in students under high cognitive load, pilots under simulated flight stress, and operators performing sustained-attention tasks consistently report preserved or improved performance on vigilance, working memory, and reaction-time measures. Sample sizes in these studies are modest by Western standards but the effect direction is consistent across settings.

Preclinical work is more rigorous and more diverse. Semax improves performance in passive avoidance, Morris water maze, and radial arm maze paradigms, reduces infarct volume in focal ischaemia models, and produces neuroprotective signals in 6-hydroxydopamine-lesioned rats and in hypoxia-tolerance studies. Transcriptomic and proteomic profiling confirms the BDNF/NGF signature and maps a broader footprint on synaptic plasticity genes.

Outside Russia, there are no completed Food and Drug Administration or European Medicines Agency registered clinical trials of Semax. Peer-reviewed replication in Western journals concentrates on mechanism of action and in-vitro pharmacology rather than clinical efficacy. Community self-reports from nootropic and biohacker forums are widespread but fall well below the evidence threshold required for formal pharmacology.

Research Dosing Protocols

Russian clinical protocols and established research-community practice converge on a dose range of 250 to 1000 mcg per administration, one to three times daily, delivered intranasally. Total daily research doses typically sit between 500 and 3000 mcg. The upper end of this range reflects the Russian stroke protocol (Semax 1 percent, roughly 2 to 3 mg per day split over three administrations), while the lower end mirrors cognitive-nootropic protocols using Semax 0.1 percent.

Four dosing schedules appear frequently in documented research settings.

Standard cognitive protocol. 250 to 500 mcg once daily in the morning on an empty stomach. This is the lightest and most common schedule, used in attention and working-memory studies and by the nootropic community as a reference dose.

Twice-daily split. 250 to 500 mcg in the morning and 250 to 500 mcg in the early afternoon. Used when sustained cognitive performance across a working day is the endpoint, and when the researcher wants to maintain consistent neurotrophin upregulation.

Russian stroke protocol. 900 to 1500 mcg three times daily (roughly 2.7 to 4.5 mg total) for 5 to 10 days following acute ischaemic event. This is the highest schedule and should only be considered in the neuroprotective research context it was designed for.

High-stress cognitive load protocol. 500 to 1000 mcg once daily, 60 to 90 minutes before the cognitive task of interest, for acute performance studies rather than chronic dosing.

A titration rationale is straightforward. Researchers typically start at 250 mcg once daily for the first two to three days to characterise nasal tolerability and response, then move to the target schedule. There is no published evidence that doses above 3000 mcg daily produce additional benefit outside the acute stroke context.

Dose-by-question framing

In research planning, the question dictates the dose. Attention and working-memory studies use 250 to 500 mcg once or twice daily. Acute performance studies use 500 to 1000 mcg one hour before task. Neuroprotection and ischaemia-recovery models use the stroke protocol or its research-scale equivalent. Sourcing from research-grade Semax with HPLC analysis is the baseline assumption for any protocol, since purity below 99 percent introduces truncated sequences that can bind melanocortin receptors with altered efficacy and confound the readout.

Reconstitution and Intranasal Delivery

Semax arrives as a lyophilised white powder in a glass vial, most commonly 10 mg (some vendors supply 5 mg or 30 mg formats). It is reconstituted with bacteriostatic water (BAC water, 0.9 percent benzyl alcohol as preservative) and transferred into a metered-dose nasal spray bottle. Critically, Semax is not injected. A BD MICRO-FINE insulin syringe may be used only as a transfer tool to draw BAC water, inject it into the vial, and withdraw the reconstituted solution into the spray bottle. The end-use device is the spray pump, not a needle.

Three reconstitution volumes produce three dose-per-spray targets. A standard metered-dose pharmaceutical spray actuates approximately 0.1 ml (100 microlitres) per pump, so ten sprays empty one millilitre of solution.

Reconstitution options for a 10 mg Semax vial

2 ml BAC water. Final concentration 5 mg/ml. Each spray delivers 500 mcg. The vial yields 20 doses. Used when the target dose is 500 mcg or 1000 mcg (two sprays in opposite nostrils).

4 ml BAC water. Final concentration 2.5 mg/ml. Each spray delivers 250 mcg. The vial yields 40 doses. This is the most common configuration for cognitive-nootropic research because 250 mcg aligns with both once-daily and twice-daily schedules.

10 ml BAC water. Final concentration 1 mg/ml. Each spray delivers 100 mcg. The vial yields 100 doses. Used for fine-grained dose-response studies and when the researcher wants granular 100 mcg increments.

Procedure

Wipe the vial septum with an alcohol swab. Draw the planned BAC water volume with a transfer syringe, insert the needle at a shallow angle, and direct the stream down the vial wall rather than onto the peptide cake. Swirl gently to dissolve, never shake. Peptide hydrogen bonds are fragile, and vigorous agitation can denature the molecule. Once dissolved, draw the solution back into the transfer syringe or a sterile pipette and dispense into a primed 5 to 10 ml metered-dose spray bottle, typically amber PET or glass. Prime the pump with two to three actuations into a tissue until a fine mist appears, then store upright refrigerated at 2 to 8 degrees Celsius. Alternate nostrils when the dose exceeds one spray.

Reconstituted Semax in BAC water is stable for 28 days at 2 to 8 degrees Celsius under preservative. For multi-dose protocols beyond 28 days, reconstitute a fresh vial and discard the previous solution. Lyophilised vials are stable for roughly 24 months at minus 20 degrees Celsius, 12 months at 2 to 8 degrees, and 6 months at room temperature if sealed. Protect from direct light.

Semax vs Selank

Both peptides were designed at the Institute of Molecular Genetics under the same Pro-Gly-Pro stabilisation strategy, and researchers encountering one inevitably hear about the other. They are not interchangeable. Selecting the wrong peptide for a given research question wastes a study. We cover the full Selank profile in our Selank research dosing guide, and the table below summarises where the two diverge.

Parameter	Semax (MEHFPGP)	Selank (TKPRPGP)
Parent motif	ACTH 4-7 fragment (melanocortin)	Tuftsin (IgG heavy chain fragment)
Molecular weight	813.93 g/mol	751.90 g/mol
Primary profile	Nootropic, neurotrophic, neuroprotective	Anxiolytic, immunomodulatory
Russian registered use	Ischaemic stroke, optic nerve atrophy, cognitive disorders	Generalised anxiety disorder, neurasthenia
BDNF/NGF upregulation	Strong, central to mechanism	Moderate
GABA-A interaction	Minimal	Allosteric modulation
Melanocortin activity	Partial MC3/MC4 engagement	None
Immune activity	Minimal	Interferon and cytokine induction
Typical research dose	250 to 1000 mcg intranasal, 1 to 3 x daily	250 to 500 mcg intranasal, 1 to 3 x daily
Acute stroke use	Yes, Russian registered indication	No

In plain terms: if the research question is cognitive performance, neuroprotection, or post-ischaemic recovery, Semax is the correct tool. If the question is anxiety without sedation or immune modulation, Selank is the better fit. Combined administration is used anecdotally in the nootropic community but is not backed by published human data, and researchers designing combination studies should treat the interaction space as unmapped.

Semax vs N-Acetyl-Semax

N-Acetyl-Semax is an acetylated analog of Semax in which the N-terminal methionine is capped with an acetyl group. N-Acetyl-Semax-Amidate adds a C-terminal amide as well. Both modifications slow peptidase cleavage further and extend the effective duration of action.

The practical difference for a researcher is duration and intensity. Unmodified Semax produces a sharp, time-limited neurotrophin pulse and is the form used in the Russian registered protocols and in most Western research-community dosing. N-Acetyl-Semax-Amidate, sometimes marketed with the shorthand NAS or NASA, extends that window and is reported anecdotally to produce a stronger subjective cognitive effect at similar milligram doses. Published clinical research on the acetylated variants is much thinner than on Semax itself, so the two should not be substituted in a protocol that cites Semax evidence.

Side Effects and Safety Profile

Published Russian human trials report a benign side-effect profile. The most commonly noted adverse event is transient nasal irritation, occasional mild headache, and rare dysgeusia (metallic taste) during or shortly after administration. Sedation, cognitive impairment, respiratory depression, and dependence syndromes are not observed in the Russian clinical literature, including at the higher stroke-protocol doses.

Preclinical acute toxicity is low, with reported rodent LD50 values well above any human-equivalent research dose. No reproductive toxicity or teratogenicity has been documented in the Russian preclinical dossier, but Western long-term human safety data beyond 30 days do not exist. Interactions with stimulants, SSRIs, and other neuroactive compounds are undercharacterised, and researchers designing combination studies should treat the interaction space as unmapped. The melanocortin arm raises a theoretical concern about chronic elevation of cortisol and blood pressure, but Russian clinical data at registered doses do not show this in practice.

COA-certified Semax from Bergdorf Bio and comparable ≥99 percent HPLC-verified sources minimise adverse events attributable to impurities. Research-use-only product is shipped in sealed lyophilised vials and should not be administered if the powder shows moisture, yellowing, or incomplete reconstitution.

Sourcing and Quality Markers

A trustworthy Semax supplier provides a Certificate of Analysis (CoA) with every batch. The CoA should list the product name and full sequence, lot number, molecular formula, molecular weight, HPLC chromatogram with explicit percent purity, mass spectrometry identity confirmation (expected [M+H]+ at m/z 814.9), Karl Fischer water content, acetate counter-ion content, appearance, manufacture date, retest date, and the signature of the quality-control analyst.

Purity at or above 99 percent by HPLC is the research standard. Below 99 percent, truncated and deletion sequences appear that may retain partial melanocortin activity but shift the dose-response relationship, producing noisy readouts. For BDNF transcriptomic endpoints, endotoxin testing below 0.25 EU per mg is additionally relevant, since lipopolysaccharide contamination will independently drive neurotrophin and cytokine expression.

Lyophilized Semax ≥99% purity from suppliers that publish batch-level CoAs is the baseline assumption in most research protocols. Research teams running parallel cognitive and immune studies often pair Semax with a diagnostic baseline, and our respiratory and influenza rapid test collection is used as a morbidity screen in longer-duration cognitive protocols during influenza-season studies.

Frequently Asked Questions

What is the typical research dose of Semax?

Research protocols use 250 to 1000 mcg intranasally, one to three times daily. Total daily doses range between 500 and 3000 mcg depending on the protocol, with the high end reserved for neuroprotection and stroke-related research.

Why is Semax given intranasally and not by injection?

Oral bioavailability is effectively zero because gastric peptidases destroy the peptide. Intranasal delivery bypasses first-pass degradation and adds a partial direct nose-to-brain route through olfactory and trigeminal pathways. The registered Russian product is also an intranasal formulation, and the research-community practice mirrors this.

How long does one Semax vial last?

A 10 mg vial reconstituted at 2.5 mg/ml yields 40 sprays of 250 mcg each. At twice-daily dosing this covers 20 research days, at once-daily dosing 40 days. Reconstituted solution in BAC water is stable for 28 days refrigerated, which is the binding limit for a single reconstitution.

What is the half-life of Semax?

The parent peptide has a plasma half-life of 2 to 5 minutes. Downstream effects via the active metabolite Pro-Gly-Pro, BDNF and NGF mRNA upregulation, and enkephalinase inhibition persist for 12 to 24 hours, which is why dosing frequency is set by downstream windows rather than plasma kinetics.

Is Semax addictive?

Russian clinical data report no withdrawal syndrome, no tolerance escalation, and no rebound cognitive impairment after discontinuation. The melanocortin mechanism is not associated with the reward circuitry that drives classical dependence.

Can Semax and Selank be combined?

Anecdotal nootropic and biohacker protocols combine the two peptides to layer the cognitive enhancement of Semax with the anxiolytic profile of Selank. Published research on combined administration is minimal. The peptides have distinct mechanisms and combination should be treated as an uncharacterised protocol rather than an established one.

What is the difference between Semax and N-Acetyl-Semax?

N-Acetyl-Semax is an acetylated analog with slower peptidase cleavage and a longer effective window. Published evidence is thinner than for Semax itself, and the two should not be substituted in a protocol. See the dedicated section above for detail.

Is Semax legal to purchase?

In the European Union and United States, Semax is unlicensed for human use and is sold exclusively as a research chemical. In Russia, it is a registered medicine for ischaemic stroke, optic nerve disorders, and cognitive indications. Researchers outside Russia should verify local rules before ordering.

How should Semax be stored?

Lyophilised vials are stable at minus 20 degrees Celsius for approximately 24 months, 2 to 8 degrees for roughly 12 months, and room temperature for 6 months if sealed. Reconstituted solution in BAC water is stable at 2 to 8 degrees for 28 days, protected from light.

Can the BD MICRO-FINE insulin syringe be used for Semax?

Only as a transfer tool during reconstitution, to move BAC water into the vial and then move reconstituted solution into the spray bottle. Semax is not injected. The end-use device is a metered-dose nasal spray pump.

What purity level should a CoA show?

At least 99 percent by HPLC with mass spectrometric identity confirmation (expected [M+H]+ at m/z 814.9). Below 99 percent, truncated sequences appear that can confound melanocortin receptor pharmacology and neurotrophin readouts.

Does Semax cause tolerance?

No tolerance has been reported in the Russian clinical literature at registered doses over 5 to 14 day courses. Long-term chronic dosing beyond 30 days has not been characterised in peer-reviewed human studies, and caution is appropriate outside the registered indications.

Conclusion

Semax is the most rigorously Russian-validated nootropic peptide in current research circulation. Its combination of strong BDNF/NGF upregulation, melanocortin engagement, and registered acute-stroke indication gives it a clinical pedigree that most research peptides cannot match, even if that pedigree sits in Russian-language literature rather than Western regulatory dossiers. Its intranasal delivery, low-milligram dosing, and long downstream effect despite a minute-scale plasma half-life make protocol design distinctive. For research teams studying cognitive performance, neuroprotection, or post-ischaemic recovery, Semax is the correct starting point. For anxiolytic or immunomodulatory questions, Selank is the better tool, and we cover that compound in depth in a dedicated guide. What Semax is not, under any EU or US regulatory framework, is an approved medicine for human use. Treat it accordingly.

Medical Disclaimer

This blog post is for informational purposes only and is not a substitute for professional medical advice. Semax is an experimental peptide outside the Russian Federation and is not approved for human use in the European Union, the United States, or most other jurisdictions. Use outside of clinical trials or approved indications is illegal in many countries.

All information regarding dosages, protocols, and applications is based on available research and user reports, but may be inaccurate or incomplete. Individual responses and safety profiles can vary significantly, and long-term human safety data beyond 30 days do not exist in the peer-reviewed literature outside the Russian registered indications.

Before using Semax or any other peptide, consult a physician or healthcare professional. This article does not endorse off-label or illegal use of Semax. The author and parahealth assume no liability for side effects, injuries, or adverse events arising from the use of information discussed in this article.

For research purposes only. Not intended for human consumption.